• Vaccine Name: NYVAC-CSP (malaria)
• Target Pathogen: malaria
• Type: Recombinant vector vaccine
• Status: Licensed
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001093
  • Description: (Lanar et al., 1996)
• Preparation: NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) (Lanar et al., 1996).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: mice were immunized intraperitoneally with 10^7 PFU of NYVAC(K1L) (vP993) parental control virus, NYVAC(K1L)CSP (vP936), NYVAC(K1L)CSPD318-332 (vP957), or NYVAC(K1L)CSPD2-21(vP1032) at week0.Some groups were boosted with the same dose of the appropriate virus at week 3 or 4 (Lanar et al., 1996).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenged either by i.v. inoculation of 10,000 sporozoites or by the bites of infected mosquitoes (Lanar et al., 1996).
• Efficacy: Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%). Protection did not correlate with CS repeat-specific antibody responses and was abrogated by in vivo CD8+ T-cell depletion. Protection was not enhanced by modification of the subcellular localization of CSP (Lanar et al., 1996).